Management of Cancer of the Prostate
- 13 October 1994
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (15) , 996-1004
- https://doi.org/10.1056/nejm199410133311507
Abstract
Prostate cancer is the second leading cause of death from cancer among men; 25 percent of men with prostate cancer die of the disease1. Moreover, many patients who do not die of prostate cancer require treatment to ameliorate symptoms such as pain, bleeding, and urinary obstruction. Thus, prostate cancer is also a major cause of suffering and of health care expenditures.The high rate of mortality from prostate cancer may be due to late detection. In recent studies, screening for prostate cancer has combined the measurement of serum prostate-specific antigen (PSA) -- the most accurate single test for the . . .Keywords
This publication has 85 references indexed in Scilit:
- Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidityInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Cancer of the prostateJAMA, 1992
- Phase I/II study of external radio frequency phased array hyperthermia and external beam radiotherapy in the treatment of prostate cancer: Technique and results of intraprostatic temperature measurementsInternational Journal of Radiation Oncology*Biology*Physics, 1992
- External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706International Journal of Radiation Oncology*Biology*Physics, 1991
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984